In elective cardiac surgery, perioperative dapagliflozin reduced acute kidney injury vs. placebo at 7 d.

In elective cardiac surgery, perioperative dapagliflozin reduced acute kidney injury compared with placebo at 7 days.

• Why it matters: Acute kidney injury after cardiac operations is a common perioperative complication, and better prevention strategies are needed to reduce early renal harm.
• What they did: The study tested perioperative dapagliflozin versus placebo in the elective cardiac surgery setting, assessing acute kidney injury at 7 days.
• The result: Dapagliflozin is linked to a lower 7-day rate of acute kidney injury than placebo, supporting its potential role in perioperative renal protection.

AI summary of the abstract · may contain errors · not medical advice · read the paper.